News
12-13-2009, 11:02 PM
Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.
More... (http://www.news-medical.net/news/20091214/Incyte-announces-positive-results-from-ongoing-Phase-III-clinical-trial-for-INCB7839.aspx)
More... (http://www.news-medical.net/news/20091214/Incyte-announces-positive-results-from-ongoing-Phase-III-clinical-trial-for-INCB7839.aspx)